[Continence problems after radical prostatectomy: medical treatment]. / Problemi di continenza dopo prostatectomia radicale: la terapia medica.

OBJECTIVE: We hypothesized that a benefit can be obtained from both urine storage and urethral resistance after retropubic radical prostatectomy through the induction of artificial erections. MATERIAL AND METHODS: From January 1993 to December 2000 we have submitted 127 patients to radical retropubic prostatectomy. According to preoperative bladder behaviour, 59 patients (46.5%) presented voiding disorders, 10 (7.9%) filling disorders, 4 (3.1%) mixed disorders, whereas 54 (42.5%) were asymptomatic. The urethral catheter was removed between the 10th and the 12th postoperative day. Fourteen patients entered a programme of early sexual rehabilitation with intracavernous injection of prostaglandin E1 (ICI) within 7 days from catheter removal. RESULTS: After catheter removal the recovery of urinary continence occurred within 2.2 +/- 2.3 days. At dismissal from the hospital, 8 patients (6.2%) were almost totally incontinent; 2 (1.5%) were still incontinent after a 6-month period; 73 (57.4%) were dismissed with clinical signs of detrusor instability hence treated with anticholinergic drugs such oxybutynin or tolterodine; 3 (2.3%) resulted obstructed after surgery because of stenosis of the anastomosis. Almost all the patients submitted to early sexual rehabilitation referred an improvement of their incontinence after the first injection. The patients who did not begin an early sexual rehabilitation generally recovered from incontinence in a longer time. CONCLUSIONS: Our preliminary observations showed that artificial erection PGE1-induced is effective in improving or accelerating post radical prostatectomy incontinence recovery. The results apply also to patients with pre-operatory detrusor instability.

[Endoscopic surgery in day hospital using bladder and urethral anesthesia with EMDA]. / Chirurgia endoscopica in Day Hospital mediante anestesia vescicale ed uretrale con EMDA.

PURPOSE: To assess the suitability of EMDA local anaesthesia for invasive procedures on lower urinary tract in one day surgery treatment. PATIENTS AND METHODS: The deep penetration of lignocaine into the bladder wall was attained by catheters, electrodes and electric current generators using revised electrochemical principles. Since 1994 203 patients with transitional cell carcinoma of the bladder underwent TURBT and 70 patients with bladder neck or prostatic obstruction underwent TURP, TUIP, TULAP; 20 patients underwent miscellaneous procedures: in 34 patients the procedures were combined. The patients' age was within 20 and 90 years (mean age 67.3). The procedures were performed in a single small endoscopic theatre annexed to the Urology Ward. A standard rigid resectoscope was used as well as a standard electrocautery (360 kHz) or a mega frequency low temperature Vesalius generator (4 MHz). Most patients received a premedication and some of them a light sedation when necessary, but all of them were fully conscious and able to complete an assessment using a simple pain scale. RESULTS: 8 out of 273 patients (3%) considered pain intolerable and other 11 (4%) reported painful but tolerable sensation, and the remaining 254 patients referred absent or minimal discomfort. Most of the patients were able to walk back to their room and go home in the evening. Those who had no chance of going back home were admitted for the night as well as those who had no assistance at all at home or those who had high probability of haemorrhage. Side effects were minimal and not related to local anesthesia: the serum lignocaine levels measured in 4 patients were innocuous. All patients experienced some tingling and reddening at the skin site of the dispersive electrode fading in a few hours. CONCLUSIONS: Local anaesthesia by using EMDA proved to be effective for most invasive endoscopic procedures in the lower urinary tract and suitable for patients undergoing day hospital surgery.

Bladder and urethral anaesthesia with electromotive drug administration (EMDA): a technique for invasive endoscopic procedures.

OBJECTIVE: To assess the efficacy of the electromotive administration of lignocaine and adrenalin as local anaesthesia (EMDA/LA) for invasive lower urinary tract procedures. PATIENTS AND METHODS: Electric current generators, catheters and electrodes were designed and fabricated, using defined electrochemical principles, to carry out EMDA/LA of the bladder and prostatic urethra of 91 patients who underwent 27 bladder-mapping biopsies, 62 transurethral resections (TURs) of bladder tumours, 21 transurethral incisions on the prostate or bladder neck incisions, 12 TURs of the prostate (122 operations in total) and nine miscellaneous interventions, all using rigid instruments. Resections were performed using electrocautery. Most patients, while minimally sedated and fully conscious, completed an assessment of EMDA/LA using a simple pain scale. RESULTS: In five of the 122 procedures, the pain was described as intolerable, six were recorded as painful but tolerable and the remaining 111 procedures were recorded as having minimal to no discomfort only. Side-effects were few, there was no clinical evidence of lignocaine toxicity and serial serum lignocaine levels measured in four patients were innocuous. CONCLUSIONS: EMDA/LA provides safe, effective anaesthesia for most invasive endoscopic procedures in the lower urinary tract.

Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study.

From July 1, 1979 to June 30, 1983, 136 consecutive patients from 5 centers in Lombardy entered a prospective randomized study to compare 500 mg. adjuvant medroxyprogesterone acetate 3 times a week for 1 year to no treatment following radical nephrectomy for category M0 renal cancer. After a median followup of 5 years (range 42 to 90 months) 40 of 120 evaluable patients (33.3 per cent) experienced relapse after a median interval free of disease of 17 months (range 2 to 74 months). Relapses occurred in 19 of 58 evaluable patients in the adjuvant treatment group (32.7 per cent) and in 21 of the 62 evaluable controls (33.9 per cent). Sex steroid hormone receptors were studied in 102 of the 120 evaluable patients with the dextran-coated charcoal technique. No significant correlation could be found among receptors, relapses and treatment. On the other hand, 33 (56.9 per cent) of the 58 treated patients experienced 39 complications related to the long-term hormonal therapy. Three patients had to discontinue medroxyprogesterone acetate for severe toxicity after 2 to 3 months. Medroxyprogesterone acetate cannot be recommended as adjuvant therapy to radical nephrectomy in patients with renal cell carcinoma.

[Hormone receptors and endocrine therapy of renal carcinoma]. / Recettori ormonali ed endocrinoterapia nel carcinoma renale.

One hundred sixty-five consecutive patients with resectable renal cancer entered a cooperative study to evaluate hormone treatment and steroid receptors. Twenty-nine patients with concomitant distant metastases (category M1) received intramuscular medroxyprogesterone acetate (MPA) 500 mg/day for at least two months after the operation. No measurable remission was observed, but 8 of 24 evaluable patients (33%) had disease stabilization for a median duration of 6 months. One hundred thirty-six cases with category M0 cancer were randomly allocated to a control group or to a treatment group with MPA 500 mg/3 times a week for one year. After a median follow-up period of over 3 years, 30 of 121 evaluable patients (24.8%) had a relapse, usually in distant sites. Relapses and survival were independent from postoperative treatment and sex. Only the extent of the disease and the presence of steroid receptors in the tumor were related with prognosis, but no relation could be found between receptors and response to hormone treatment. The presence of low concentrations of hormone receptors in a proportion of renal cancers remains unclear. However, MPA is confirmed to be only marginally active in metastatic renal cancer and the drug cannot be recommended as adjuvant to radically resected patients because of significant toxicity and lack of therapeutic activity.

Adjunctive medroxyprogesterone acetate to radical nephrectomy in category M0 renal cell carcinoma. Preliminary report of a prospective randomized trial.

From July 1979 to December 1981, 83 patients from 6 centers in the Lombardy underwent radical nephrectomy for category M0 renal cell carcinoma. Postoperatively they were randomly allocated to adjunctive medroxyprogesterone acetate (MPA) or to a control group. After the first year of follow-up, the relapse rate was 13% in the controls (5 of 38 evaluable patients) versus 28% in the MPA treatment group (9 of 32). Sex steroid receptors were studied in both the tumor and in the surrounding healthy parenchyma by the dextran-coated charcoal technique in 52 of 70 clinically evaluable patients. There was no significant correlation between receptor studies and the relapse rate. Besides, receptors were more often detected in the healthy than in the neoplastic tissue, and values rarely exceeded 10 fmol/mg protein. Due to the negative trend in the MPA treatment group, the admittance of patients to this study was stopped after 120 patients had been accepted.